🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Carl G. Maki

Rush University Medical Center

ORCID: 0000-0002-1207-2250

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer”.

Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer

Cancers(2022)10.3390/cancers14030739

N/A

0DataRank · unranked

6 citations

Sarah Calhoun, Ricardo E. Perez, Virgilia Macias, Fatima Mir, Melissa R. Pergande +4 more

CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor

Scientific Reports(2023)10.1038/s41598-023-43218-3

N/A

0DataRank · unranked

8 citations

Mehrdad Jafari Tadi, Carl G. Maki, Lei Duan

Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells

Journal of Biological Chemistry(2024)10.1016/j.jbc.2024.107375

N/A

0DataRank · unranked

7 citations

Mehrdad Jafari Tadi, Kelsey M. O’Hara, Carl G. Maki, Lei Duan

Determinants of Aurora kinase B inhibitor sensitivity in small cell lung cancer

Translational Lung Cancer Research(2024)10.21037/tlcr-23-732

N/A

0DataRank · unranked

2 citations

Carl G. Maki, Lei Duan

Potential biomarkers for MCL1 inhibitor sensitivity

Cell Signaling(2024)10.46439/signaling.2.046

N/A

0DataRank · unranked

0 citations

Carl G. Maki, Lei Duan